Related Experiment Video
Updated: Jul 7, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
Published on: March 7, 2022
Sodium nitroprusside as a nitric oxide donor in a rat intestinal ischemia-reperfusion model
Ali Emre1, Orhan Bayram, Bulent Salman
1General Surgery, Zonguldak Karaelmas University, Turkey. auemre@gmail.com
Aim:
The aim of this study was to investigate the efficacy of sodium nitroprusside in the reduction of the intestinal ischemia-reperfusion injury as a nitric oxide donor after intraperitoneal administration.
Methods:
The histopathological examinations and tissue malonyldialdehyde levels of 35 Wistar albino rats that were subjected to ischemia-reperfusion, were performed in 5 groups. The groups include Control, Ischemia -reperfusion, Sodium nitroprusside, NG-Nitro-L-Arginine Methyl Ester (L-NAME) and Sodium nitroprusside+L-NAME. Each rat was subjected to ischemia for 40 minutes and reperfusion for 30 minutes, except the control group. The medications were done intraperitoneally as saline 4 ml/kg, Sodium nitroprusside 5 mg/kg, L-NAME 10 mg/kg just before reperfusions.
Results:
Significant tissue injury in histological sections and an increase in tissue levels of Malonyldialdehyde was detected in the I/R group. The efficacy of intraperitoneal administration of Sodium nitroprusside in both Sodium nitroprusside alone and Sodium nitroprusside+L-NAME groups was found statistically significant for the reducing of injury scores (p<0.05). The difference between the Ischemia/reperfusion and Sodium nitroprusside groups was found statistically significant as in the Ischemia/reperfusion and Sodium nitroprusside+L-NAME groups due to the tissue Malonyldialdehyde levels (p<0.05). There was no statistical difference between Ischemia/reperfusion and L-NAME groups.
Conclusion:
Ischemia/reperfusion induced injury might be reduced by the intraperitoneal administration of Sodium nitroprusside, even in the presence of L-NAME, in the rat intestinal model.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Nitric Oxide Signaling Pathway